NBTX: Nanobiotix Group Price Target Chart

Corporate company logo of Nanobiotix Corp (NBTX)

Nanobiotix S.A. (NBTX) develops advanced nanomedicines to enhance the efficacy of tumor irradiation, which are currently undergoing final testing and preparing for commercialization. This Franco-American firm's operations rely on unique developments in radiology and partnerships with clinics. This historical price chart reflects the dynamics of the asset, which has a value of 55.53, while the business faces strict FDA oversight and patent restrictions.

NBTX - Nanobiotix SA Consensus Target over the range 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for Nanobiotix Corp (NBTX)

- stock price and consensus target price:
Share Price nanobiotix.com|NBTX - Analyst Consensus Forecast
- market capitalization information:
Market Value Nanobiotix Corp|NBTX - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Price of a Share Nanobiotix|NBTX - Company Net Assets|Capitalization to Book Value Ratio nanobiotix.com|NBTX - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Capital Nanobiotix S.A.|NBTX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Nanobiotix Group|NBTX - Company Aggregate Debts|Debt to Book Value Nanobiotix Corp|NBTX - Company Long-Term Debt|Short-Term Debt Nanobiotix|Quick Liquidity nanobiotix.com
- earnings and market ratios statistics:
NBTX - Company Net Income|Expected Net Profit Nanobiotix S.A.|NBTX - P/E Multiple|Forward Price to Earnings Multiple Nanobiotix SA|NBTX - Price/Earnings to Growth Multiple|Company Value to EBITDA Nanobiotix Corp|NBTX - Operating profit before deduction of amortization|Earnings per share for the trailing year Nanobiotix|NBTX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months nanobiotix.com|NBTX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Nanobiotix S.A.
General company analysis:NBTX (nanobiotix.com)
Mass-produced product of nanobiotix.com

The consensus forecast determines the asset's fundamental margin of safety through the weighted average expectation of analysts. This consensus valuation chart visualizes the gap between the current price and the fair value. The metric measures growth potential, identifying whether the security is undervalued or overbought. For Nanobiotix S.A. (NBTX), this indicator is critical due to high scientific development risks. It helps assess the value of technologies amidst competition with biotech behemoths.

Competitors of Nanobiotix S.A.

geron.com - Broker Consensus Forecast|Analyst Consensus Forecast BCYC (Bicycle Therapeutics plc)|CytomX Pharma - Price Target Chart|CATX: Consensus Target|Genelux Corporation - Analyst Forecast Prices|MOLN (Molecular Partners) - Consensus Target|Broker Consensus Forecast ONCY|Price Target Chart Lisata Therapeutics Inc.|Average Forecast Price Moleculin MBRX|Price Target Chart Galera Therapeutics (GRTX)|Molecular Templates Corporation - Broker Consensus Forecast